1
|
Singh J, Yadav AK, Pakhare A, Kulkarni P, Lokhande L, Soni P, Dadheech M, Gupta P, Masarkar N, Maurya AK, Nema S, Biswas D, Singh S. Comparative analysis of the diagnostic performance of five commercial COVID-19 qRT PCR kits used in India. Sci Rep 2021; 11:22013. [PMID: 34759300 PMCID: PMC8580981 DOI: 10.1038/s41598-021-00852-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2021] [Accepted: 08/23/2021] [Indexed: 02/07/2023] Open
Abstract
To meet the unprecedented requirement of diagnostic testing for SARS-CoV-2, a large number of diagnostic kits were authorized by concerned authorities for diagnostic use within a short period of time during the initial phases of the ongoing pandemic. We undertook this study to evaluate the inter-test agreement and other key operational features of 5 such commercial kits that have been extensively used in India for routine diagnostic testing for COVID-19. The five commercial kits were evaluated, using a panel of positive and negative respiratory samples, considering the kit provided by National Institute of Virology, Indian Council of Medical Research (2019-nCoV Kit) as the reference. The positive panel comprised of individuals who fulfilled the 3 criteria of being clinically symptomatic, having history of contact with diagnosed cases and testing positive in the reference kit. The negative panel included both healthy and disease controls, the latter being drawn from individuals diagnosed with other respiratory viral infections. The same protocol of sample collection, same RNA extraction kit and same RT-PCR instrument were used for all the kits. Clinical samples were collected from a panel of 92 cases and 60 control patients, who fulfilled our inclusion criteria. The control group included equal number of healthy individuals and patients infected with other respiratory viruses (n = 30, in each group). We observed varying sensitivity and specificity among the evaluated kits, with LabGun COVID-19 RT-PCR kit showing the highest sensitivity and specificity (94% and 100% respectively), followed by TaqPath COVID-19 Combo and Allplex 2019-nCoV assays. The extent of inter-test agreement was not associated with viral loads of the samples. Poor correlation was observed between Ct values of the same genes amplified using different kits. Our findings reveal the presence of wide heterogeneity and sub-optimal inter-test agreement in the diagnostic performance of the evaluated kits and hint at the need of adopting stringent standards for fulfilling the quality assurance requirements of the COVID-19 diagnostic process.
Collapse
Affiliation(s)
- J Singh
- Department of Microbiology, All India Institute of Medical Sciences, Bhopal, 462020, India
- Translational Medicine Centre, All India Institute of Medical Sciences, Bhopal, India
| | - A K Yadav
- Department of Microbiology, All India Institute of Medical Sciences, Bhopal, 462020, India
| | - A Pakhare
- Department of Community & Family Medicine, All India Institute of Medical Sciences, Bhopal, India
| | - P Kulkarni
- Department of Biochemistry, All India Institute of Medical Sciences, Bhopal, India
| | - L Lokhande
- Department of Microbiology, All India Institute of Medical Sciences, Bhopal, 462020, India
| | - P Soni
- Department of Microbiology, All India Institute of Medical Sciences, Bhopal, 462020, India
| | - M Dadheech
- Department of Microbiology, All India Institute of Medical Sciences, Bhopal, 462020, India
| | - P Gupta
- Department of Microbiology, All India Institute of Medical Sciences, Bhopal, 462020, India
| | - N Masarkar
- Department of Biochemistry, All India Institute of Medical Sciences, Bhopal, India
| | - A K Maurya
- Department of Microbiology, All India Institute of Medical Sciences, Bhopal, 462020, India
| | - S Nema
- Department of Microbiology, All India Institute of Medical Sciences, Bhopal, 462020, India
| | - D Biswas
- Department of Microbiology, All India Institute of Medical Sciences, Bhopal, 462020, India.
| | - S Singh
- Department of Microbiology, All India Institute of Medical Sciences, Bhopal, 462020, India.
| |
Collapse
|
2
|
Lokhande L, Emruli V, Kolstad A, Hutchings M, Räty R, Rodrigues J, Jerkeman M, Ek S. SERUM BIOMARKERS ARE ASSOCIATED WITH TREATMENT RESPONSE IN RELAPSED MANTLE CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.72_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- L. Lokhande
- Department of Immunotechnology; Lund University; Lund Sweden
| | - V.K. Emruli
- Department of Immunotechnology; Lund University; Lund Sweden
| | - A. Kolstad
- Department of Oncology; Oslo University Hospital; Oslo Norway
| | - M. Hutchings
- Department of Haematology; Rigshospitalet; Copenhagen Copenhagen Denmark
| | - R. Räty
- Department of Hematology; Helsinki University Central Hospital; Helsinki Finland
| | - J.D. Rodrigues
- Department of Immunotechnology; Lund University; Lund Sweden
| | - M. Jerkeman
- Department of Oncology; Skane University Hospital; Lund Sweden
| | - S. Ek
- Department of Immunotechnology; Lund University; Lund Sweden
| |
Collapse
|
3
|
Rodrigues J, Freiburghaus C, Carlsson A, Husby S, Eskelund C, Lokhande L, Kolstad A, Grønbaek K, Jerkeman M, Ek S. THE IMMUNE MICROENVIRONMENT AS A PROGNOSTIC TOOL FOR MCL PATIENTS. Hematol Oncol 2019. [DOI: 10.1002/hon.6_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- J.M. Rodrigues
- Department of Immunotechnology; Lund University; Lund Sweden
| | - C. Freiburghaus
- Department of Immunotechnology; Lund University; Lund Sweden
| | | | - S. Husby
- Department of Haematology; Rigshospitalet; Copenhagen Denmark
| | - C.W. Eskelund
- Department of Haematology; Rigshospitalet; Copenhagen Denmark
| | - L. Lokhande
- Department of Immunotechnology; Lund University; Lund Sweden
| | - A. Kolstad
- Department of Oncology; Division of Cancer Medicine, Oslo University Hospital; Oslo Norway
| | - K. Grønbaek
- Department of Haematology; Rigshospitalet; Copenhagen Denmark
| | - M. Jerkeman
- Department of Oncology; Lund University; Lund Sweden
| | - S. Ek
- Department of Immunotechnology; Lund University; Lund Sweden
| |
Collapse
|